Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

DOI Full Paper Access

186

Citations

28

References

2015

Year

Michel Farnier, Peter J.H. Jones, Randall Severance, Maurizio Averna, Elisabeth Steinhagen‐Thiessen, Helen M. Colhoun, Yunling Du, Corinne Hanotin, Stephen Donahue

Atherosclerosis

Abstract

The addition of alirocumab to rosuvastatin provided incremental LDL-C lowering versus adding ezetimibe or doubling the rosuvastatin dose.

References

	Year	Citations

Page 1